Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
E: timothy.power@bms.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,847.60 | 205.10 | -2.55% |
| CAC 40 | 7,598.98 | 259.85 | -3.31% |
| DAX 40 | 21,717.39 | 673.45 | -3.01% |
| Dow JONES (US) | 40,545.93 | 1,679.39 | -3.98% |
| FTSE 100 | 8,474.74 | 133.74 | -1.55% |
| HKSE | 22,849.81 | 352.72 | -1.52% |
| NASDAQ | 16,550.61 | 1,050.44 | -5.97% |
| Nikkei 225 | 33,603.72 | 1,132.21 | -3.26% |
| NZX 50 Index | 12,225.28 | 113.29 | -0.92% |
| S&P 500 | 5,396.52 | 274.45 | -4.84% |
| S&P/ASX 200 | 7,667.80 | 191.90 | -2.44% |
| SSE Composite Index | 3,342.01 | 8.12 | -0.24% |